News

Investing becomes an easier process the moment that you shift from a trading mindset to an ownership approach. That transformation begins when you realize that behind every stock ticker, there's a

Dividend stocks can be great additions to anyone's portfolio, and it's even better to buy quality ones when they're down. While the market has roared back this year following a downturn in 2022, it

Dividend stocks can be great additions to anyone's portfolio, and it's even better to buy quality ones when they're down. While the market has roared back this year following a downturn in 2022, it

As conventional investment wisdom has it, it's best to buy low and sell high. However, that only works when you have solid reasons to believe a company's shares will bounce back meaningfully after a

Viatris (NASDAQ: VTRS) spun off from Pfizer and merged with Mylan back in 2020. It's a generic drugmaker with a diverse, global business that serves patients and customers in over 165 countries and

Viatris (NASDAQ: VTRS) spun off from Pfizer and merged with Mylan back in 2020. It's a generic drugmaker with a diverse, global business that serves patients and customers in over 165 countries and

There's nothing like a surge in a deadly disease to encourage investors back into a noted healthcare stock. This dynamic benefited biotech Novavax (NASDAQ: NVAX) on Thursday.

It was also on the back

Shares of MacroGenics (NASDAQ: MGNX) were up more than 24% as of 11:45 a.m. on Thursday after the biotech company announced second-quarter earnings. The stock is down more than 7% so far this year.

Abbott Laboratories (NYSE: ABT) posted its latest earnings numbers last month, and there's reason to be optimistic about the business. Although a drop in COVID testing means sales are down overall

Biogen (NASDAQ: BIIB) is an intriguing stock right now. Its business has struggled to generate growth in recent years, but some recent catalysts could turn things around. For starters, the company's

Biogen (NASDAQ: BIIB) is an intriguing stock right now. Its business has struggled to generate growth in recent years, but some recent catalysts could turn things around. For starters, the company's

Biogen (NASDAQ: BIIB) is an intriguing stock right now. Its business has struggled to generate growth in recent years, but some recent catalysts could turn things around. For starters, the company's

Investing for income may never be the most exciting investment strategy in the world. But as long as a company doesn't cut or suspend its dividend, it can be a profitable approach -- and some

Biotech company Vertex Pharmaceuticals (NASDAQ: VRTX) has made for a solid investment over the past decade, more than quadrupling in value during that period. The stock generated fantastic returns

Biotech company Vertex Pharmaceuticals (NASDAQ: VRTX) has made for a solid investment over the past decade, more than quadrupling in value during that period. The stock generated fantastic returns

Biotech company Vertex Pharmaceuticals (NASDAQ: VRTX) has made for a solid investment over the past decade, more than quadrupling in value during that period. The stock generated fantastic returns

The cost of living is getting more and more expensive. This is because inflation steadily diminishes the value of the U.S. dollar over time, and the purchasing power of said dollar as a result.

One

The cost of living is getting more and more expensive. This is because inflation steadily diminishes the value of the U.S. dollar over time, and the purchasing power of said dollar as a result.

One

The cost of living is getting more and more expensive. This is because inflation steadily diminishes the value of the U.S. dollar over time, and the purchasing power of said dollar as a result.

One

Merck (NYSE: MRK) has performed poorly in the stock market this year, with the drugmaker's shares down by 5%. But zooming out helps put a different spin on this story as the pharmaceutical giant has

If you look at the S&P 500, which is up more than 18% this year, or the Nasdaq Composite, which is up more than 34% in 2023, it appears the markets are booming. If you look specifically at biotech

If you look at the S&P 500, which is up more than 18% this year, or the Nasdaq Composite, which is up more than 34% in 2023, it appears the markets are booming. If you look specifically at biotech

If you look at the S&P 500, which is up more than 18% this year, or the Nasdaq Composite, which is up more than 34% in 2023, it appears the markets are booming. If you look specifically at biotech